{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T03:13:13Z","timestamp":1785294793302,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Obtusofolin is the major active ingredient of Catsia tora L., which possesses the activity of improving eyesight and protecting the optic nerve. Investigation on the interaction of obtusofolin with cytochrome P450 enzymes (CYP450s) could provide a reference for the clinical application of obtusofolin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The effect of obtusofolin on the activity of CYP450s was investigated in the presence of 100\u2009\u03bcM obtusofolin in pooled human liver microsomes (HLMs) and fitted with the Lineweaver\u2013Burk plots to characterize the specific inhibition model and kinetic parameters.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Obtusofolin was found to significantly inhibited the activity of CYP3A4, 2C9, and 2E1. In the presence of 0, 2.5, 5, 10, 25, 50, and 100\u2009\u03bcM obtusofolin, the inhibition of these CYP450s showed a dose-dependent manner with the IC<jats:sub>50<\/jats:sub> values of 17.1\u2009\u00b1\u20090.25, 10.8\u2009\u00b1\u20090.13, and 15.5\u2009\u00b1\u20090.16\u2009\u03bcM, respectively. The inhibition of CYP3A4 was best fitted with the non-competitive inhibition model with the <jats:italic>K<\/jats:italic><jats:sub><jats:italic>i<\/jats:italic><\/jats:sub> value of 8.82\u2009\u03bcM. While the inhibition of CYP2C9 and 2E1 was competitive with the <jats:italic>K<\/jats:italic><jats:sub><jats:italic>i<\/jats:italic><\/jats:sub> values of 5.54 and 7.79\u2009\u03bcM, respectively. After incubating for 0, 5, 10, 15, and 30\u2009min, the inhibition of CYP3A4 was revealed to be time-dependent with the <jats:italic>K<\/jats:italic><jats:sub><jats:italic>I<\/jats:italic><\/jats:sub> value of 4.87\u2009\u03bcM<jats:sup>\u2212\u20091<\/jats:sup> and the <jats:italic>K<\/jats:italic><jats:sub><jats:italic>inact<\/jats:italic><\/jats:sub> value of 0.0515\u2009min<jats:sup>\u2212\u20091<\/jats:sup>.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The in vitro inhibitory effect of obtusofolin implying the potential drug-drug interaction between obtusofolin and corresponding substrates, which needs further in vivo validations.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12906-021-03397-w","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T16:03:36Z","timestamp":1630512216000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["In vitro inhibitory effect of obtusofolin on the activity of CYP3A4, 2C9, and 2E1"],"prefix":"10.1186","volume":"21","author":[{"given":"Na","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxia","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,1]]},"reference":[{"issue":"16","key":"3397_CR1","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1002\/jssc.201200009","volume":"35","author":"WD Zhang","year":"2012","unstructured":"Zhang WD, Wang Y, Wang Q, Yang WJ, Gu Y, Wang R, et al. Quality evaluation of semen Cassiae (Cassia obtusifolia L.) by using ultra-high performance liquid chromatography coupled with mass spectrometry. J Sep Sci. 2012;35(16):2054\u201362. https:\/\/doi.org\/10.1002\/jssc.201200009.","journal-title":"J Sep Sci"},{"issue":"6","key":"3397_CR2","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1055\/s-0042-102458","volume":"82","author":"SY Zhuang","year":"2016","unstructured":"Zhuang SY, Wu ML, Wei PJ, Cao ZP, Xiao P, Li CH. Changes in plasma lipid levels and antioxidant activities in rats after supplementation of Obtusifolin. Planta Med. 2016;82(6):539\u201343. https:\/\/doi.org\/10.1055\/s-0042-102458.","journal-title":"Planta Med"},{"issue":"10","key":"3397_CR3","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1248\/bpb.c14-00307","volume":"37","author":"ZW He","year":"2014","unstructured":"He ZW, Wei W, Li SP, Ling Q, Liao KJ, Wang X. Anti-allodynic effects of obtusifolin and gluco-obtusifolin against inflammatory and neuropathic pain. Biol Pharm Bull. 2014;37(10):1606\u201316. https:\/\/doi.org\/10.1248\/bpb.c14-00307.","journal-title":"Biol Pharm Bull"},{"issue":"3","key":"3397_CR4","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1007\/s12013-014-0124-0","volume":"70","author":"Y Tang","year":"2014","unstructured":"Tang Y, Zhong Z. Obtusifolin treatment improves hyperlipidemia and hyperglycemia: possible mechanism involving oxidative stress. Cell Biochem Biophys. 2014;70(3):1751\u20137. https:\/\/doi.org\/10.1007\/s12013-014-0124-0.","journal-title":"Cell Biochem Biophys"},{"issue":"2","key":"3397_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1254\/jphs.08286FP","volume":"111","author":"DH Kim","year":"2009","unstructured":"Kim DH, Hyun SK, Yoon BH, Seo JH, Lee KT, Cheong JH, et al. Gluco-obtusifolin and its aglycon, obtusifolin, attenuate scopolamine-induced memory impairment. J Pharmacol Sci. 2009;111(2):110\u20136. https:\/\/doi.org\/10.1254\/jphs.08286FP.","journal-title":"J Pharmacol Sci"},{"issue":"3","key":"3397_CR6","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s12013-014-0109-z","volume":"70","author":"B Hou","year":"2014","unstructured":"Hou B, He S, Gong Y, Li Z. Effect of obtusifolin administration on retinal capillary cell death and the development of retinopathy in diabetic rats. Cell Biochem Biophys. 2014;70(3):1655\u201361. https:\/\/doi.org\/10.1007\/s12013-014-0109-z.","journal-title":"Cell Biochem Biophys"},{"issue":"10","key":"3397_CR7","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.18240\/ijo.2019.10.04","volume":"12","author":"LF Wang","year":"2019","unstructured":"Wang LF, Yan ZY, Li YL, Wang YH, Zhang SJ, Jia X, et al. Inhibition of Obtusifolin on retinal pigment epithelial cell growth under hypoxia. Int J Ophthalmol. 2019;12(10):1539\u201347. https:\/\/doi.org\/10.18240\/ijo.2019.10.04.","journal-title":"Int J Ophthalmol"},{"issue":"1","key":"3397_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2174\/1389450118666170125144557","volume":"19","author":"P Manikandan","year":"2018","unstructured":"Manikandan P, Nagini S. Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets. 2018;19(1):38\u201354. https:\/\/doi.org\/10.2174\/1389450118666170125144557.","journal-title":"Curr Drug Targets"},{"issue":"4","key":"3397_CR9","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/jcph.1557","volume":"60","author":"J Greger","year":"2020","unstructured":"Greger J, Bates V, Mechtler L, Gengo F. A review of cannabis and interactions with anticoagulant and antiplatelet agents. J Clin Pharmacol. 2020;60(4):432\u20138. https:\/\/doi.org\/10.1002\/jcph.1557.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"3397_CR10","doi-asserted-by":"publisher","first-page":"e0195624","DOI":"10.1371\/journal.pone.0195624","volume":"13","author":"SH Jang","year":"2018","unstructured":"Jang SH, Yang DK. The combination of Cassia obtusifolia L. and Foeniculum vulgare M. exhibits a laxative effect on loperamide-induced constipation of rats. PLoS One. 2018;13(4):e0195624.","journal-title":"PLoS One"},{"issue":"8","key":"3397_CR11","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1080\/00498254.2020.1727062","volume":"50","author":"B Ding","year":"2020","unstructured":"Ding B, Ji X, Sun X, Zhang T, Mu S. In vitro effect of pachymic acid on the activity of cytochrome P450 enzymes. Xenobiotica. 2020;50(8):913\u20138. https:\/\/doi.org\/10.1080\/00498254.2020.1727062.","journal-title":"Xenobiotica"},{"issue":"5\u20136","key":"3397_CR12","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1159\/000502172","volume":"104","author":"L Wang","year":"2019","unstructured":"Wang L, Ma X, Wang J, Li C. In vitro inhibitory effects of Cynaroside on human liver cytochrome P450 enzymes. Pharmacology. 2019;104(5\u20136):296\u2013302. https:\/\/doi.org\/10.1159\/000502172.","journal-title":"Pharmacology."},{"issue":"2","key":"3397_CR13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1365-2125.2009.03572.x","volume":"69","author":"ZZ Fang","year":"2010","unstructured":"Fang ZZ, Zhang YY, Ge GB, Huo H, Liang SC, Yang L. Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction. Br J Clin Pharmacol. 2010;69(2):193\u20139. https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03572.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"3397_CR14","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1080\/00498254.2018.1558309","volume":"49","author":"L Liu","year":"2019","unstructured":"Liu L, Cao X, Li T, Li X. Effects of catalpol on the activity of human liver cytochrome P450 enzymes. Xenobiotica. 2019;49(11):1289\u201395. https:\/\/doi.org\/10.1080\/00498254.2018.1558309.","journal-title":"Xenobiotica"},{"issue":"3","key":"3397_CR15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.cbi.2004.03.003","volume":"147","author":"K Monostory","year":"2004","unstructured":"Monostory K, Hazai E, Vereczkey L. Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004;147(3):331\u201340. https:\/\/doi.org\/10.1016\/j.cbi.2004.03.003.","journal-title":"Chem Biol Interact"},{"issue":"2","key":"3397_CR16","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s11418-013-0794-8","volume":"68","author":"Y Pan","year":"2014","unstructured":"Pan Y, Tiong KH, Abd-Rashid BA, Ismail Z, Ismail R, Mak JW, et al. Effect of eurycomanone on cytochrome P450 isoforms CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2E1 and CYP3A4 in vitro. J Nat Med. 2014;68(2):402\u20136. https:\/\/doi.org\/10.1007\/s11418-013-0794-8.","journal-title":"J Nat Med"},{"issue":"1","key":"3397_CR17","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1080\/13880209.2017.1299769","volume":"55","author":"V Sreelakshmi","year":"2017","unstructured":"Sreelakshmi V, Abraham A. Protective effects of Cassia tora leaves in experimental cataract by modulating intracellular communication, membrane co-transporters, energy metabolism and the ubiquitin-proteasome pathway. Pharm Biol. 2017;55(1):1274\u201382. https:\/\/doi.org\/10.1080\/13880209.2017.1299769.","journal-title":"Pharm Biol"},{"issue":"3","key":"3397_CR18","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/cpt.967","volume":"104","author":"M Drozdzik","year":"2018","unstructured":"Drozdzik M, Busch D, Lapczuk J, Muller J, Ostrowski M, Kurzawski M, et al. Protein abundance of clinically relevant drug-metabolizing enzymes in the human liver and intestine: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther. 2018;104(3):515\u201324. https:\/\/doi.org\/10.1002\/cpt.967.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"3397_CR19","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1080\/13880209.2019.1688844","volume":"57","author":"J Liu","year":"2019","unstructured":"Liu J, Zhang N, Li N, Fan X, Li Y. Influence of verapamil on the pharmacokinetics of oridonin in rats. Pharm Biol. 2019;57(1):787\u201391. https:\/\/doi.org\/10.1080\/13880209.2019.1688844.","journal-title":"Pharm Biol"},{"issue":"1","key":"3397_CR20","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1080\/13880209.2020.1717550","volume":"58","author":"H Xing","year":"2020","unstructured":"Xing H, Luo X, Li Y, Fan C, Liu N, Cui C, et al. Effect of verapamil on the pharmacokinetics of hydroxycamptothecin and its potential mechanism. Pharm Biol. 2020;58(1):152\u20136. https:\/\/doi.org\/10.1080\/13880209.2020.1717550.","journal-title":"Pharm Biol"},{"issue":"12","key":"3397_CR21","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1002\/jcph.1476","volume":"59","author":"J Ramirez","year":"2019","unstructured":"Ramirez J, House LK, Karrison TG, Janisch LA, Turcich M, Salgia R, et al. Prolonged pharmacokinetic interaction between Capecitabine and a CYP2C9 substrate. Celecoxib J Clin Pharmacol. 2019;59(12):1632\u201340. https:\/\/doi.org\/10.1002\/jcph.1476.","journal-title":"Celecoxib J Clin Pharmacol"},{"issue":"5","key":"3397_CR22","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2174\/138920007780866807","volume":"8","author":"AS Kalgutkar","year":"2007","unstructured":"Kalgutkar AS, Obach RS, Maurer TS. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. Curr Drug Metab. 2007;8(5):407\u201347. https:\/\/doi.org\/10.2174\/138920007780866807.","journal-title":"Curr Drug Metab"},{"key":"3397_CR23","doi-asserted-by":"publisher","unstructured":"Huang Z, Sun Q, Hao W, Zhao J. Pharmacokinetics and tissue distribution study of obtusifolin in rats by liquid chromatography-tandem mass spectrometry. Biomed Chromatogr. 2020;35(3):e5009. https:\/\/doi.org\/10.1002\/bmc.5009.","DOI":"10.1002\/bmc.5009"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-021-03397-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-021-03397-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-021-03397-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T16:05:05Z","timestamp":1630512305000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-021-03397-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3397"],"URL":"https:\/\/doi.org\/10.1186\/s12906-021-03397-w","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,1]]},"assertion":[{"value":"26 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"218"}}